CD

CJC-1295 with DACIntroductionCJC-1295 with DAC (Drug Affinity Complex) is a long-acting analog of growth hormone-releasing hormone (GHRH) with significantly extended half-life and bioactivity. Below is a detailed introduction to CJC-1295 with DAC.
Mechanism of Action
• Drug Affinity Complex (DAC): DAC is a molecular attachment that enables CJC-1295 to bind with albumin in the plasma, thereby significantly prolonging its half-life in the bloodstream. This binding protects the peptide from rapid degradation, allowing CJC-1295 with DAC to maintain activity for up to 6 to 8 days after injection.
• Growth Hormone Release: CJC-1295 stimulates the natural production of growth hormone (GH) in the body by binding to receptors in the anterior pituitary gland, rather than introducing exogenous growth hormone. This mechanism helps maintain a healthy hormonal balance and reduces the risks associated with the use of exogenous hormones.Advantages
• Extended Half-life: Compared to regular CJC-1295, the half-life of CJC-1295 with DAC is extended from less than 10 minutes to 6 to 8 days.
• Reduced Injection Frequency: Due to its extended half-life, CJC-1295 with DAC typically requires only 1 to 2 injections per week to maintain stable levels of growth hormone and IGF-1.
• Sustained Growth Hormone Release: This long-acting mode of action makes CJC-1295 with DAC excel in muscle growth, fat breakdown, joint and tissue repair, as well as anti-aging.